FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4239392382> ?p ?o ?g. }

• W4239392382 endingPage "855" @default.
• W4239392382 startingPage "847" @default.
• W4239392382 abstract "Background: Human papillomavirus (HPV) type 16/18 AS04-adjuvanted vaccine was shown to be highly immunogenic and generally well tolerated in the interim analysis of a phase 2 double-blind, randomized controlled multicenter study in Japanese healthy women aged 20 to 25 years. Vaccine efficacy, immunogenicity, and safety are assessed in this study through 24 months after the first vaccination. Methods: Japanese women aged 20 to 25 years were randomly assigned to receive either HPV-16/18 AS04-adjuvanted vaccine (n = 519) or hepatitis A vaccine (n = 521) at 0, 1, and 6 months. Women were assessed for virological, cytological, and histological end points associated with HPV-16/18 and 12 other oncogenic HPV types (types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) in cervical specimens and for the vaccine safety and immunogenicity. Antibody concentrations were measured by an enzyme-linked immunosorbent assay. Primary efficacy analysis was performed in the according-to-protocol cohort for efficacy, primary immunogenicity analysis was performed in the according-to-protocol cohort for immunogenicity, and primary safety analysis was done in the total vaccinated cohort. Results: Vaccine efficacy against persistent infections (6 month definition) associated with HPV-16/18 was 100% (95.5% confidence interval, 71.3-100; P < 0.0001). Vaccine efficacy against cervical intraepithelial neoplasia 1+ associated with 14 oncogenic HPV types was 64.9% (95.5% confidence interval, 4.9-89.0; P = 0.02). At 24 months after the first dose of the vaccine, geometric mean antibody titers against HPV-16 and HPV-18 were 1521.5 enzyme-linked immunosorbent assay U/mL and 627.4 enzyme-linked immunosorbent assay U/mL, respectively. The HPV-16/18 AS04-adjuvanted vaccine had a clinically acceptable safety profile. Conclusions: The HPV-16/18 AS04-adjuvanted vaccine showed excellent prophylactic efficacy against 6-month persistent infection with HPV-16/18. The HPV-16/18 AS04-adjuvanted vaccine was generally well tolerated and immunogenic in the study population of healthy Japanese women aged 20 to 25 years." @default.
• W4239392382 created "2022-05-12" @default.
• W4239392382 creator A5007226526 @default.
• W4239392382 creator A5011118237 @default.
• W4239392382 creator A5028795531 @default.
• W4239392382 creator A5087115407 @default.
• W4239392382 date "2010-06-01" @default.
• W4239392382 modified "2023-09-23" @default.
• W4239392382 title "Efficacy of Human Papillomavirus Type 16/18 AS04-Adjuvanted Vaccine in Japanese Women Aged 20 to 25 Years: Final Analysis of a Phase 2 Double-Blind, Randomized Controlled Trial" @default.
• W4239392382 cites W1965782309 @default.
• W4239392382 cites W1988984928 @default.
• W4239392382 cites W1991256849 @default.
• W4239392382 cites W1994125256 @default.
• W4239392382 cites W2047580791 @default.
• W4239392382 cites W2095156171 @default.
• W4239392382 cites W2095794160 @default.
• W4239392382 cites W2098491904 @default.
• W4239392382 cites W2103347596 @default.
• W4239392382 cites W2114391710 @default.
• W4239392382 cites W2117586539 @default.
• W4239392382 cites W2127248987 @default.
• W4239392382 cites W2135053575 @default.
• W4239392382 cites W2136236728 @default.
• W4239392382 cites W2150436558 @default.
• W4239392382 cites W2157554614 @default.
• W4239392382 cites W2159831861 @default.
• W4239392382 cites W2168280828 @default.
• W4239392382 cites W2332729004 @default.
• W4239392382 doi "https://doi.org/10.1111/igc.0b013e3181da2128" @default.
• W4239392382 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20606533" @default.
• W4239392382 hasPublicationYear "2010" @default.
• W4239392382 type Work @default.
• W4239392382 citedByCount "28" @default.
• W4239392382 countsByYear W42393923822012 @default.
• W4239392382 countsByYear W42393923822013 @default.
• W4239392382 countsByYear W42393923822014 @default.
• W4239392382 countsByYear W42393923822015 @default.
• W4239392382 countsByYear W42393923822016 @default.
• W4239392382 countsByYear W42393923822017 @default.
• W4239392382 countsByYear W42393923822018 @default.
• W4239392382 countsByYear W42393923822019 @default.
• W4239392382 countsByYear W42393923822020 @default.
• W4239392382 countsByYear W42393923822022 @default.
• W4239392382 crossrefType "journal-article" @default.
• W4239392382 hasAuthorship W4239392382A5007226526 @default.
• W4239392382 hasAuthorship W4239392382A5011118237 @default.
• W4239392382 hasAuthorship W4239392382A5028795531 @default.
• W4239392382 hasAuthorship W4239392382A5087115407 @default.
• W4239392382 hasConcept C121608353 @default.
• W4239392382 hasConcept C126322002 @default.
• W4239392382 hasConcept C159047783 @default.
• W4239392382 hasConcept C159654299 @default.
• W4239392382 hasConcept C168563851 @default.
• W4239392382 hasConcept C197934379 @default.
• W4239392382 hasConcept C203014093 @default.
• W4239392382 hasConcept C22070199 @default.
• W4239392382 hasConcept C2778190748 @default.
• W4239392382 hasConcept C2778220009 @default.
• W4239392382 hasConcept C2778580637 @default.
• W4239392382 hasConcept C2780009117 @default.
• W4239392382 hasConcept C2780441014 @default.
• W4239392382 hasConcept C2780868878 @default.
• W4239392382 hasConcept C44249647 @default.
• W4239392382 hasConcept C61943457 @default.
• W4239392382 hasConcept C71924100 @default.
• W4239392382 hasConcept C72563966 @default.
• W4239392382 hasConceptScore W4239392382C121608353 @default.
• W4239392382 hasConceptScore W4239392382C126322002 @default.
• W4239392382 hasConceptScore W4239392382C159047783 @default.
• W4239392382 hasConceptScore W4239392382C159654299 @default.
• W4239392382 hasConceptScore W4239392382C168563851 @default.
• W4239392382 hasConceptScore W4239392382C197934379 @default.
• W4239392382 hasConceptScore W4239392382C203014093 @default.
• W4239392382 hasConceptScore W4239392382C22070199 @default.
• W4239392382 hasConceptScore W4239392382C2778190748 @default.
• W4239392382 hasConceptScore W4239392382C2778220009 @default.
• W4239392382 hasConceptScore W4239392382C2778580637 @default.
• W4239392382 hasConceptScore W4239392382C2780009117 @default.
• W4239392382 hasConceptScore W4239392382C2780441014 @default.
• W4239392382 hasConceptScore W4239392382C2780868878 @default.
• W4239392382 hasConceptScore W4239392382C44249647 @default.
• W4239392382 hasConceptScore W4239392382C61943457 @default.
• W4239392382 hasConceptScore W4239392382C71924100 @default.
• W4239392382 hasConceptScore W4239392382C72563966 @default.
• W4239392382 hasIssue "5" @default.
• W4239392382 hasLocation W42393923821 @default.
• W4239392382 hasLocation W42393923822 @default.
• W4239392382 hasOpenAccess W4239392382 @default.
• W4239392382 hasPrimaryLocation W42393923821 @default.
• W4239392382 hasRelatedWork W1715936078 @default.
• W4239392382 hasRelatedWork W1972778802 @default.
• W4239392382 hasRelatedWork W1976418033 @default.
• W4239392382 hasRelatedWork W2028361003 @default.
• W4239392382 hasRelatedWork W2065692446 @default.
• W4239392382 hasRelatedWork W2093927228 @default.
• W4239392382 hasRelatedWork W2102632609 @default.
• W4239392382 hasRelatedWork W2907319927 @default.
• W4239392382 hasRelatedWork W2910203053 @default.

• next